Merional(Merional) - 药物靶点：LHCGR_在研适应症：无排卵_专利_临床

概要

基本信息

药物类型

激素

别名

human menopausal gonadotropin( IBSA Institut Biochimique SA)

靶点

LHCGR

作用方式

激动剂

作用机制

LHCGR激动剂(促黄体激素/绒毛膜促性腺激素受体激动剂)

治疗领域

内分泌与代谢疾病泌尿生殖系统疾病

在研适应症

无排卵

非在研适应症

多囊卵巢综合征

原研机构

IBSA Institut Biochimique SA

在研机构

Ibsa Farmaceutici Italia Srl

非在研机构

Saudi German Hospitals Group

权益机构-

最高研发阶段批准上市

首次获批日期

(2009-03-02),

无排卵

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

10

项与 Merional 相关的临床试验

NCT04754243

/ Recruiting临床4期IIT

A Higher Ovulation and Pregnancy Rates in Patients With Unexplained Infertility After Application of ANTIUI Protocol: A Randomized Multicenter Controlled Study

The new protocol ANTIUI provides good results regarding ovulation and pregnancy rates in patients with unexplained infertility

开始日期2021-03-01

申办/合作机构

Tanta University

IRCT20151013024512N7

/ Completed临床2期IIT

A comparison of the effect of intraovarian injection of autologous platelet rich plasma (PRP) versus PRP plus gonadotropin and gonadotropin alone on ovarian rejuvenation in patients with diminished ovarian reserve

开始日期2021-02-15

申办/合作机构-

NCT04537078

/ Completed临床3期IIT

Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders

The worldwide prevalence of primary and secondary infertility is estimated at
2% and 10.5%, respectively, among women aged 20-44 years and attempting to conceive. Poor ovarian responders (PORs) involve 9-24% of patients undergoing in-vitro fertilization (IVF). proper tailoring of the ovarian stimulation protocol in order to maximize the number of oocytes collected represents a crucial step for them to eventually conceive.
Recent evidence indicates that in the same menstrual cycle, there are multiple follicular recruitment waves. This coincides with the theory that folliculogenesis occurs in a wave-like fashion. Thus, within a single menstrual cycle, there can theoretically be multiple opportunities for a clinician to collect oocytes, as opposed to the conventional single cohort of antral follicles during the follicular phase.
Utilizing this concept, clinicians have been attempting to retrieve oocytes from poor responders using both the follicular-phase stimulation (FPS) and the luteal-phase stimulation (LPS) protocols to increase the number of oocytes collected shorter within shorter period of time. By increasing the number of the retrieved oocytes collected, a better clinical can be assured since there is a clear relationship between the number of oocytes collected and live birth rates across all female age groups.
which protocol is the most effective remains controversial and the efficacy of PPOS in POR compared with that of conventional protocols is unclear.

开始日期2020-09-01

申办/合作机构-

100 项与 Merional 相关的临床结果

登录后查看更多信息

100 项与 Merional 相关的转化医学

登录后查看更多信息

100 项与 Merional 相关的专利（医药）

登录后查看更多信息

621

项与 Merional 相关的文献（医药）

2025-03-01·Fertility and Sterility

An umbrella review of meta-analyses regarding the incidence of female-specific malignancies after fertility treatment

Review

作者: Al-Memar, Maya ; Bourne, Tom ; Smith, J Richard ; Timmerman, Dirk ; Verbakel, Jan Y ; Getreu, Natalie ; Saso, Srdjan ; Galazis, Nicolas ; Ní Dhonnabháin, Bríd ; Mitra, Anita ; Ghaem-Maghami, Sadaf ; Ben-Nagi, Jara ; Kasaven, Lorraine S ; Grewal, Karen J ; Chan, Maxine ; Barcroft, Jen F ; Yazbek, Joseph ; Bracewell-Milnes, Timothy ; Jones, Benjamin P

IMPORTANCEUnderstanding the potential risks associated with fertility treatments (FTs) can guide clinical decision and patient counseling.OBJECTIVETo investigate the validity of the association between the development of female-specific malignancies including ovarian, endometrial, breast, and cervical cancer after FT.DATA SOURCESA search of systematic reviews and meta-analyses was performed from inception to April 2022 within several databases: Cochrane Database of Systematic Reviews, EMBASE, Google Scholar, and PubMed.STUDY SELECTION AND SYNTHESISThe inclusion criteria required the incidence of each cancer subgroup to be stated in both the defined treatment group (controlled ovarian stimulation and/or in vitro fertilization [IVF] or intracytoplasmic sperm injection) and the control group (no-FT, general population). From 3,129 identified publications, 11 meta-analytical reviews consisting of 188 studies were selected for synthesis.MAIN OUTCOMEThe primary outcome of interest was incidence of each subgroup of cancer in the "FT" group compared with the "no-FT" group.RESULTSA statistically significant increase in incidence of ovarian (1,229/430,611 in FT group vs. 27,358/4,263,300 in no-FT group) cancer (odds ratio [OR], 1.21; 95% confidence interval [CI], 1.00-1.45) and borderline ovarian tumors (117/414,729 in FT group vs. 934/2,626,324 in no-FT group) (OR, 1.87; 95% CI, 1.18-2.97) was observed. The incidence of ovarian cancer was higher with FT and IVF specifically (OR, 1.65; 95% CI, 1.07-2.54). For borderline ovarian tumors, the incidence was higher, not only with FT overall and IVF, but also according to the fertility drug regimen applied: clomiphene citrate (CC) only (OR, 1.99; 95% CI, 1.02-3.87), human menopausal gonadotropin only (OR, 3.46; 95% CI, 1.39-8.59), and CC and human menopausal gonadotropin combined (OR, 3.79; 95% CI, 1.47-9.77). When using the threshold for statistical significance, the meta-analyses relevant to ovarian cancers remained statistically significant (random-effects method). However, none of the examined associations could claim either strong or highly suggestive evidence.CONCLUSION AND RELEVANCEAn observed association between ovarian cancer (including borderline ovarian tumors) and FT has been demonstrated. The association between FT and female-specific malignancy remains a contentious topic because there have been contradictory outcomes among meta-analyses. This umbrella review interrogates existing systematic reviews and meta-analyses on this topic and concludes that a statistically significant increase in the incidence of ovarian cancer and borderline ovarian tumors is associated with FT. These findings have a significant clinical impact because it helps to inform and provide effective counseling for patients undergoing FT.

2024-12-31·Česká gynekologie

Comparing highly purified human menopausal gonadotropin and recombinant follicle stimulating hormone in poor ovarian reserve patients undergoing intracytoplasmic sperm injection

Article

作者: Tutar, Mahmut Sami ; Akgun, Humeyra ; Gunenc, Oguzhan ; Dogru, Sukran ; Korucu, Dilay Gok

Objective: We aimed to compare highly purified human menopausal gonadotropin (hp-hMG) and recombinant follicle stimulating hormone (rFSH) in short antagonist in vitro fertilization (IVF) cycles of patients with poor ovarian reserve (POR). Limited research exists on this comparison in short antagonist cycles for this patient group. Materials and methods: This retrospective cohort study involved 165 POR patients aged 18–45 years who underwent IVF between 2018 and 2022. Patients were divided into two groups based on their GnRH antagonist protocol: hp-hMG (group 1 = 72) and rFSH (group 2 = 93). We compared pregnancy outcomes, number of oocytes collected, mature oocytes retrieved, mean fertilized oocytes, top quality embryos transferred, and serum estradiol (E2) and progesterone (P) levels on human chorionic gonadotropin (hCG) administration day. Results: No significant differences were found in E2 and P levels on hCG trigger day, endometrial thickness on transfer day, stimulation duration, total oocyte number, and mature oocyte number (P > 0.05). The total gonadotropin dose was significantly higher in the rFSH group (P < 0.001). The number of top-quality embryos transferred and clinical pregnancy and live birth rates did not diff er significantly between groups (P = 0.320; P = 0.310; P = 0.652; and P = 0.662, resp.). Conclusion: Neither hp-hMG nor rFSH showed superiority in patients with POR, indicating similar effectiveness in this population. Key words: highly purified human menopausal gonadotropin – in vitro fertilization – live birth – poor ovarian reserve – recombinant follicle stimulating hormone

2024-12-01·Iranian biomedical journal

25th National and 11th International Annual Congress on Research and Technology of Iranian Medical Sciences Students, Urmia, Iran, 5-7 September, 2024

Article

作者: Khadem Ghaebi, Nayyereh ; Joghatayi, Farzaneh ; Morovatdar, Negar ; Pousti, Navid ; Afzaljavan, Fahimeh ; Afiat, Maliheh

IntroductionInfertility is a severe challenge for most health systems. One of the medications recently used for ovulation induction is letrozole, applied either alone or in combination with gonadotropin. The present study was conducted to compare ovulation induction in infertile polycystic ovarian syndrome (PCOS) women candidates of intrauterine insemination (IUI) who were resistant to letrozole by two regimens: single-drug stair step letrozole vs. combined letrozole plus human menopausal gonadotropin.Methods and MaterialsIn this parallel randomized clinical trial, 60 infertile women with PCOS, candidates for intrauterine insemination, admitted to Milad Infertility Center at Imam Reza Hospital, Mashhad, Iran, were randomly assigned into two groups. The intervention group received 5 mg of letrozole for five days from menstruation day 3 and 7.5 mg of letrozole for another five days if dominant follicles were not observed on days 14-19. Control cases received letrozole (5 mg) from day 3 of the cycle for five days plus Cinnal-f® (75 international units subcutaneously daily) on days 8 and 9. They received another dose of Cinnal-f® if the dominant follicle was not observed on days 10-12 of the cycle. In the case of detecting dominant follicles, 5000 units of intramuscular hCG were prescribed, and 36 hours later, the patients underwent IUI. The outcomes were considered, and data were analyzed using SPSS.ResultsAlmost 70% of the stair-step letrozole group and 53.2% in the combined medication had a dominant follicle (p = 0.12), mainly observed after day 14 in the stair-step letrozole group and during days 10-14 in the letrozole/gonadotropin group (p = 0.001). The positive beta-hCG level was significantly higher in the stair-step letrozole group (23.3%) than in the letrozole/gonadotropin group (13.3%). The clinical pregnancy and gestations of 20 weeks or beyond (ongoing pregnancy) were 16.66% and 10% in the stair-step letrozole and letrozole/gonadotropin groups, respectively (p = 0.03).Conclusion and DiscussionOur study found similar frequencies of dominant follicles between the stair-step letrozole and letrozole/ gonadotropin groups and a significantly higher frequency of chemical pregnancy (positive beta-hCG) and clinical and ongoing pregnancy in the stair-step letrozole group. As an easy and acceptable method for patients, this protocol can be a suitable alternative for ovulation induction.

100 项与 Merional 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
无排卵	-	Ibsa Farmaceutici Italia Srl	2009-03-02

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多囊卵巢综合征	药物发现	沙特阿拉伯	Saudi German Hospitals Group	2019-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESPE2022	N/A	软骨-头发发育不良	72	gonadotropin	繭遞憲憲選遞顧網繭觸(鑰淵簾製網夢鑰築壓鬱) = 願壓艱糧構憲製壓糧蓋顧蓋鬱壓壓壓艱顧壓憲 (積襯願艱淵鏇鹹齋鹽願, 48) 更多	-	2022-09-15
				gonadotropin	繭遞憲憲選遞顧網繭觸(鑰淵簾製網夢鑰築壓鬱) = 夢醖淵醖餘廠鏇鬱窪鹹顧蓋鬱壓壓壓艱顧壓憲 (積襯願艱淵鏇鹹齋鹽願, 54) 更多
NCT04537078 (CTgov)	临床3期	女性不孕症	90	Combined Oral Contraceptive+Decapeptyl+Cyclo-Progynova+progesterone+Gonadotropin+Duphaston (the Progestin Primed Double Stimulation Group)	鹽齋壓廠網鑰獵網積願(製襯鑰構齋醖齋網艱夢) = 遞壓醖壓蓋蓋衊範顧衊繭憲遞夢觸觸齋窪網觸 (廠願衊鹽簾繭襯齋網廠, 簾顧網憲鏇鬱積醖簾糧 ~ 淵鏇網壓齋顧願淵窪襯) 更多	-	2022-02-17
				Combined Oral Contraceptive+Cetrotide Injectable Product+Decapeptyl+Chorionic Gonadotropin+Cyclo-Progynova+progesterone+Gonadotropin (the Flexible GnRh Antagonist)	願憲艱遞夢簾齋鬱築願(鹹範繭餘鹽衊繭構壓鏇) = 觸齋獵繭窪願鑰製製艱衊鏇襯艱繭夢選願鑰夢 (遞襯簾蓋醖夢鬱鹹願鏇, 鹹糧壓衊艱壓願築顧鑰 ~ 選淵襯鏇襯顧網簾糧構) 更多